The evidence is mixed3 supporting, 3 against, 0 worth knowing
Supporting
matches near a 52-week low, which has beaten the market by +0.38 points over 20 sessions across 48,405 past signals
revenue grew 11% year on year in the quarter ending 30 June 2026
net margin has widened from 13.0% to 13.8% across four quarters
Against
trading 9% below its 200-day average
at 4% of its 52-week range — nearly everyone who bought in the past year is underwater
down 22% over twelve months
Worth knowing
nothing the data supports either way
What would change this read: a close back above 397, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working3
Profit rose year on year in all 4 of the last 4 quarters.
4
Revenue rose 11.3% year on year, from Rs 365 cr to Rs 406 cr.
+11.3%Rs 365 crRs 406 cr
Net profit rose 8.5% year on year, from Rs 51 cr to Rs 56 cr.
+8.5%Rs 51 crRs 56 cr
Needs watching5
Trading 9.3% below its 200-day average.
-9.3%
42% below its 52-week high.
-42%
Only 3.0% above its 52-week low.
+3.0%
Down 22.3% over the past year.
-22.3%
A warning rule fires on it tonight: near a 52-week low.
Near a 52-week low
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 3 of these 3 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
3 of 47 matched on 10 Sep
INDRAMEDCO matches 3 of the 47 scans today, across 2 different kinds of evidence.
INDRAMEDCO trades at 18× trailing earnings, below its median of 24× over this window — 28% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202) · AGM / EGM filings were typically +0.17pt vs the market over the next 5 sessions (n=8,423) · Results filings were typically -0.51pt vs the market over the next 5 sessions (n=7,726)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 11% against the same quarter a year earlier
profit rose 9% year on year
net margin widened from 11.4% to 13.8%
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · standalone
406
75
56
6.09
13.8%
Q4 FY26
31 Mar · standalone
365
55
42
4.55
11.4%
Q3 FY26
31 Dec · standalone
372
56
41
4.47
11.0%
Q2 FY26
30 Sep · standalone
381
66
49
5.40
13.0%
Q1 FY26
30 Jun · standalone
365
68
51
5.61
14.1%
Q4 FY25
31 Mar · standalone
334
55
41
4.47
12.3%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-2.7%
Versus 200-day average-9.3%
Below 52-week high-42.2%
Above 52-week low+3.0%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)39.3
Higher closes in last 53 of 5
Six-month return−11.58%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.